Colorectal cancer highlights from ASCO 2025 include findings from the BREAKWATER, ATOMIC, DYNAMIC-III, and TRIPLETE trials.

Significantly longer progression-free and overall survival seen in patients with BRAF V600E mutations.

Fulgent Genetics is evolving into a precision medicine player with strong cash reserves, despite expected near-term losses.

Recent advances in RAS-targeted therapies revolutionize treatment for gastrointestinal cancers, promising improved outcomes and new clinical strategies for oncologists.

Phase 2 study, led by Dr. Antonio Jimeno at the University of Colorado Anschutz Medical Campus will evaluate NT219 in ...

SAN DIEGO, June 13, 2025 /PRNewswire/ — Rakuten Medical, Inc., a global biotechnology company developing and commercializing Alluminox™ platform-based photoimmunotherapy, today announced that it was ...

Purple Biotech Ltd. ("Purple Biotech" or "the Company") (NASDAQ/TASE: PPBT), a clinical-stage company developing first-in-class therapies that seek to overcome tumor immune evasion and drug resistance ...

HealthDay News — For patients with BRAF V600E-mutated metastatic colorectal cancer, progression-free and overall survival are significantly longer with encorafenib plus cetuximab (EC) plus ...

A phase II clinical trial led by the Alliance for Clinical Trials in Oncology has met its primary endpoint, demonstrating that the combination of avelumab and cetuximab improved progression-free ...

Merck & Co., Inc. (NYSE:MRK) has announced promising early results from its Phase 1 KANDLELIT-001 trial of MK-1084, an investigational KRAS G12C inhibitor, in patients with advanced colorectal cancer ...

Cetuximab (Erbitux) plus chemotherapy showed higher progression-free survival (PFS) and overall survival (OS) for patients with metastatic colorectal cancer (mCRC), according to one study.

Key Takeaways. The FDA approved encorafenib, cetuximab, and mFOLFOX6 for mCRC with BRAF V600E mutation, based on the BREAKWATER trial results. The trial showed a 61% ORR for the combination ...